Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Siyue Jia
Observed names:
S Y Jia,
Shiwei Jia,
Si-Yue Jia
Institutions:
Charles Sturt University,
Jiangsu Provincial Center for Disease Control and Prevention,
Renmin University of China,
Nanjing Medical University
Observed institutions:
Charles Sturt University,
Jiangsu Provincial Center for Disease Control and Prevention,
Renmin University of China,
Nanjing Medical University
ORCID:
0000-0002-0648-4507
Observed ORCID:
0000-0002-0648-4507
OpenAlex ID:
A5048201566
Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial
2020
·
Feng-Cai Zhu
, Xu-Hua Guan
, et al.
·
The Lancet
·
1,252
PDF
Safety and immunogenicity of the SARS-CoV-2 BNT162b1 mRNA vaccine in younger and older Chinese adults: a randomized, placebo-controlled, double-blind phase 1 study
2021
·
Jingxin Li
, Aimin Hui
, et al.
·
Nature Medicine
·
133
PDF
Safety, immunogenicity and protection of heterologous boost with an aerosolised Ad5-nCoV after two-dose inactivated COVID-19 vaccines in adults: a multicentre, open-label phase 3 trial
2023
·
Jing-Xin Li
, Li-Hua Hou
, et al.
·
The Lancet Infectious Diseases
·
63
PDF
Safety and immunogenicity of a recombinant COVID-19 vaccine (Sf9 cells) in healthy population aged 18 years or older: two single-center, randomised, double-blind, placebo-controlled, phase 1 and phase 2 trials
2021
·
Fan-Yue Meng
, Fan Gao
, et al.
·
Signal Transduction and Targeted Therapy
·
37
PDF
Precision immunization: a new trend in human vaccination
2019
·
Siyue Jia
, Jingxin Li
, et al.
·
Human Vaccines & Immunotherapeutics
·
17
PDF
Relative effectiveness of a heterologous booster dose with adenovirus type 5 vectored COVID-19 vaccine versus three doses of inactivated COVID-19 vaccine in adults during a nationwide outbreak of omicron predominance, in China: a retrospective, individually matched cohort-control study
2024
·
Siyue Jia
, Zundong Yin
, et al.
·
Emerging Microbes & Infections
·
10
PDF
The effect of maternal poliovirus antibodies on the immune responses of infants to poliovirus vaccines
2020
·
Siyue Jia
, Rong Tang
, et al.
·
BMC Infectious Diseases
·
9
PDF
Immune Persistence and Safety After SARS-CoV-2 BNT162b1 mRNA Vaccination in Chinese Adults: A Randomized, Placebo-Controlled, Double-Blind Phase 1 Trial
2022
·
Jingxin Li
, Ai-Min Hui
, et al.
·
Advances in Therapy
·
8
PDF
Effectiveness of a booster dose of aerosolized or intramuscular adenovirus type 5 vectored COVID-19 vaccine in adults: a multicenter, partially randomized, platform trial in China
2025
·
Siyue Jia
, Yuanbao Liu
, et al.
·
Nature Communications
·
7
Safety and immunogenicity of a novel quadrivalent subunit influenza vaccine in animal models
2020
·
Huayue Ye
, Siyue Jia
, et al.
·
Human Vaccines & Immunotherapeutics
·
7
Immunogenicity and safety of a COVID-19 DNA vaccine in healthy adults and elderly: A randomized, observer-blind, placebo-controlled phase 2 trial
2025
·
Siyue Jia
, Chengwei Shao
, et al.
·
Human Vaccines & Immunotherapeutics
·
6
PDF
Coronavirus disease 2019 vaccines: landscape of global studies and potential risks
2021
·
Hu-Da-Chuan Jiang
, Yan-Yang Tao
, et al.
·
Chinese Medical Journal
·
5
A head-to-head comparison of humoral and cellular immune responses of five COVID-19 vaccines in adults in China
2024
·
Xu Han
, Hongxing Pan
, et al.
·
Frontiers in Immunology
·
3
Safety and Immunogenicity of Homologous Recombinant Adenovirus Type 5-Vectored COVID-19 Vaccine Booster Dose in Healthy Adults Aged 18–60 Years: a Single-Center, Open-Label Trial
2023
·
Siyue Jia
, Jinlong Zhang
, et al.
·
Infectious Diseases and Therapy
·
3
PDF
The Factors Influencing the Incidence, Persistence, and Severity of Symptoms After SARS-CoV-2 Infection in Chinese Adults: A Case–Control Study
2025
·
Weixiao Wang
, Runjie Qi
, et al.
·
Tropical Medicine and Infectious Disease
·
2
PDF
Immunogenicity and safety of a booster dose of the COVID-19 DNA vaccine in healthy adults aged 18 years and above: a single-center, randomized, observer-blind, placebo-controlled phase 2 trial
2025
·
Aihua Yao
, Siyue Jia
, et al.
·
BMC Infectious Diseases
·
2
PDF
Adverse reaction characteristics of five COVID-19 vaccines across different technology platforms: a pooled analysis of nine clinical trials
2025
·
Yue Liu
, Qian Liu
, et al.
·
Expert Review of Vaccines
·
2
PDF
[Exploration and application of a novel attempt to recruit participants in clinical trials of vaccines under the emergency].
2020
·
H D C Jiang
, Z Wang
, et al.
·
PubMed
·
2
A predictive model for rapid assessment of protective efficacy against emerging SARS-CoV-2 variants
2026
·
Lairun Jin
, Siyue Jia
, et al.
·
Infectious Disease Modelling
·
1
Deep Mutational Scanning in Immunology: Techniques and Applications
2025
·
Chengwei Shao
, Siyue Jia
, et al.
·
Pathogens
·
1
PDF
Immunogenicity and safety of two-dose or three-dose regimens of inactivated COVID-19 vaccines in patients with pulmonary tuberculosis: a randomised clinical trial
2024
·
Pengfei Jin
, Qiao Liu
, et al.
·
Expert Review of Vaccines
·
1
Challenges of COVID-19 vaccination in patients with cancer
2022
·
Siyue Jia
, Wenbo Zhu
, et al.
·
National Science Open
·
1
Safety, Tolerability and Immunogenicity of a Recombinant Adenovirus Type 5 Vectored COVID-19 Vaccine in Healthy Adults in China: Preliminary Report of a First-In Human Single-Center, Open-Label, Dose-Escalating Clinical Trial
2020
·
Feng-Cai Zhu
, Yu-Hua Li
, et al.
·
SSRN Electronic Journal
·
1
Integrated Plasma Proteomic and Single-Cell Transcriptomic Profiling of Three COVID-19 Second-Booster Regimens: An Exploratory Analysis of a Randomized Phase IV Trial
2026
·
Weixiao Wang
, Hui Zheng
, et al.
·
Vaccines
Conceptualizing algorithmic inequality and future agenda. An annual review of information science and technology (ARIST) paper
2026
·
Shiwei Jia
, Jia Tina Du
, et al.
·
Journal of the Association for Information Science and Technology
PDF
Show more works
View as search
Works count:
33
Citation count:
1,653
H-index:
8
I10-index:
6
Year
Topic
Type